Tarter Krinsky & Drogin LLP represented the lead investors in a $3.15 million senior secured convertible debenture investment in Proectus Pharmaceuticals, Inc., a developer of pharmaceuticals and medical devices. Corporate Associate Arthur Zagorsky represented the lead investors